Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell and taste disorders
IntroductionCurrent approved COVID-19 vaccines, notably mRNA and adenoviral vectored technologies, still fail to fully protect against infection and transmission of various SARS-CoV-2 variants. The mucosal immunity at the upper respiratory tract represents the first line of defense against respirato...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1140714/full |
| _version_ | 1811158364039675904 |
|---|---|
| author | Jessica Denis Annabelle Garnier Laurence Cheutin Audrey Ferrier Hawa Timera Fanny Jarjaval Carine Hejl Carine Hejl Emmanuelle Billon-Denis Percy ImmunoCovid group Damien Ricard Damien Ricard Damien Ricard Jean-Nicolas Tournier Jean-Nicolas Tournier Aurélie Trignol Aurélie Trignol Marie Mura Marie Mura |
| author_facet | Jessica Denis Annabelle Garnier Laurence Cheutin Audrey Ferrier Hawa Timera Fanny Jarjaval Carine Hejl Carine Hejl Emmanuelle Billon-Denis Percy ImmunoCovid group Damien Ricard Damien Ricard Damien Ricard Jean-Nicolas Tournier Jean-Nicolas Tournier Aurélie Trignol Aurélie Trignol Marie Mura Marie Mura |
| author_sort | Jessica Denis |
| collection | DOAJ |
| description | IntroductionCurrent approved COVID-19 vaccines, notably mRNA and adenoviral vectored technologies, still fail to fully protect against infection and transmission of various SARS-CoV-2 variants. The mucosal immunity at the upper respiratory tract represents the first line of defense against respiratory viruses such as SARS-CoV-2 and is thus critical to develop vaccine blocking human-to-human transmission.MethodsWe measured systemic and mucosal Immunoglobulin A (IgA) response in serum and saliva from 133 healthcare workers from Percy teaching military hospital following a mild infection (SARS-CoV-2 Wuhan strain, n=58) or not infected (n=75), and after SARS-CoV-2 vaccination (Vaxzevria®/Astrazeneca and/or Comirnaty®/Pfizer).ResultsWhile serum anti-SARS-CoV-2 Spike IgA response lasted up to 16 months post-infection, IgA response in saliva had mostly fallen to baseline level at 6 months post-infection. Vaccination could reactivate the mucosal response generated by prior infection, but failed to induce a significant mucosal IgA response by itself. Early post-COVID-19 serum anti-Spike-NTD IgA titer correlated with seroneutralization titers. Interestingly, its saliva counterpart positively correlated with persistent smell and taste disorders more than one year after mild COVID-19.DiscussionAs breakthrough infections have been correlated with IgA levels, other vaccine platforms inducing a better mucosal immunity are needed to control COVID-19 infection in the future. Our results encourage further studies to explore the prognosis potential of anti-Spike-NTD IgA in saliva at predicting persistent smell and taste disorders. |
| first_indexed | 2024-04-10T05:22:11Z |
| format | Article |
| id | doaj.art-38ea015d0956408d9d46b6e816a63fb4 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T05:22:11Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-38ea015d0956408d9d46b6e816a63fb42023-03-08T05:51:52ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-03-011410.3389/fimmu.2023.11407141140714Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell and taste disordersJessica Denis0Annabelle Garnier1Laurence Cheutin2Audrey Ferrier3Hawa Timera4Fanny Jarjaval5Carine Hejl6Carine Hejl7Emmanuelle Billon-Denis8Percy ImmunoCovid groupDamien Ricard9Damien Ricard10Damien Ricard11Jean-Nicolas Tournier12Jean-Nicolas Tournier13Aurélie Trignol14Aurélie Trignol15Marie Mura16Marie Mura17Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale de Armées, Brétigny-sur-Orge, FranceMicrobiology and Infectious Diseases Department, Institut de Recherche Biomédicale de Armées, Brétigny-sur-Orge, FranceMicrobiology and Infectious Diseases Department, Institut de Recherche Biomédicale de Armées, Brétigny-sur-Orge, FranceMicrobiology and Infectious Diseases Department, Institut de Recherche Biomédicale de Armées, Brétigny-sur-Orge, FranceMicrobiology and Infectious Diseases Department, Institut de Recherche Biomédicale de Armées, Brétigny-sur-Orge, FranceMicrobiology and Infectious Diseases Department, Institut de Recherche Biomédicale de Armées, Brétigny-sur-Orge, FranceHôpital d’Instruction des Armées Percy, Clamart, FranceEcole du Val-de-Grâce, Paris, FranceMicrobiology and Infectious Diseases Department, Institut de Recherche Biomédicale de Armées, Brétigny-sur-Orge, FranceHôpital d’Instruction des Armées Percy, Clamart, FranceEcole du Val-de-Grâce, Paris, FranceCentre Borelli Unité Mixte de Recherche (UMR) 9010/Université Paris-Saclay, ENS Paris-Saclay, Centre National de la Recherche Scientifique (CNRS), Service de Santé des Armées (SSA), Université de Paris Cité, Institut National de la Santé et de la Recherche Médicale (INSERM) 4, Gif-sur-Yvette, FranceMicrobiology and Infectious Diseases Department, Institut de Recherche Biomédicale de Armées, Brétigny-sur-Orge, FranceEcole du Val-de-Grâce, Paris, FranceMicrobiology and Infectious Diseases Department, Institut de Recherche Biomédicale de Armées, Brétigny-sur-Orge, FranceUniversité Paris Cité, VIFASOM (UPR 7330 Vigilance Fatigue, Sommeil et Santé Publique), Paris, FranceMicrobiology and Infectious Diseases Department, Institut de Recherche Biomédicale de Armées, Brétigny-sur-Orge, FranceInnovation Lab: Vaccines, Institut Pasteur, Paris, FranceIntroductionCurrent approved COVID-19 vaccines, notably mRNA and adenoviral vectored technologies, still fail to fully protect against infection and transmission of various SARS-CoV-2 variants. The mucosal immunity at the upper respiratory tract represents the first line of defense against respiratory viruses such as SARS-CoV-2 and is thus critical to develop vaccine blocking human-to-human transmission.MethodsWe measured systemic and mucosal Immunoglobulin A (IgA) response in serum and saliva from 133 healthcare workers from Percy teaching military hospital following a mild infection (SARS-CoV-2 Wuhan strain, n=58) or not infected (n=75), and after SARS-CoV-2 vaccination (Vaxzevria®/Astrazeneca and/or Comirnaty®/Pfizer).ResultsWhile serum anti-SARS-CoV-2 Spike IgA response lasted up to 16 months post-infection, IgA response in saliva had mostly fallen to baseline level at 6 months post-infection. Vaccination could reactivate the mucosal response generated by prior infection, but failed to induce a significant mucosal IgA response by itself. Early post-COVID-19 serum anti-Spike-NTD IgA titer correlated with seroneutralization titers. Interestingly, its saliva counterpart positively correlated with persistent smell and taste disorders more than one year after mild COVID-19.DiscussionAs breakthrough infections have been correlated with IgA levels, other vaccine platforms inducing a better mucosal immunity are needed to control COVID-19 infection in the future. Our results encourage further studies to explore the prognosis potential of anti-Spike-NTD IgA in saliva at predicting persistent smell and taste disorders.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1140714/fullmucosal immunitySARS-CoV2 vaccinedysosmiadysgeusiaIgASpike N-terminal domain |
| spellingShingle | Jessica Denis Annabelle Garnier Laurence Cheutin Audrey Ferrier Hawa Timera Fanny Jarjaval Carine Hejl Carine Hejl Emmanuelle Billon-Denis Percy ImmunoCovid group Damien Ricard Damien Ricard Damien Ricard Jean-Nicolas Tournier Jean-Nicolas Tournier Aurélie Trignol Aurélie Trignol Marie Mura Marie Mura Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell and taste disorders Frontiers in Immunology mucosal immunity SARS-CoV2 vaccine dysosmia dysgeusia IgA Spike N-terminal domain |
| title | Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell and taste disorders |
| title_full | Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell and taste disorders |
| title_fullStr | Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell and taste disorders |
| title_full_unstemmed | Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell and taste disorders |
| title_short | Long-term systemic and mucosal SARS-CoV-2 IgA response and its association with persistent smell and taste disorders |
| title_sort | long term systemic and mucosal sars cov 2 iga response and its association with persistent smell and taste disorders |
| topic | mucosal immunity SARS-CoV2 vaccine dysosmia dysgeusia IgA Spike N-terminal domain |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1140714/full |
| work_keys_str_mv | AT jessicadenis longtermsystemicandmucosalsarscov2igaresponseanditsassociationwithpersistentsmellandtastedisorders AT annabellegarnier longtermsystemicandmucosalsarscov2igaresponseanditsassociationwithpersistentsmellandtastedisorders AT laurencecheutin longtermsystemicandmucosalsarscov2igaresponseanditsassociationwithpersistentsmellandtastedisorders AT audreyferrier longtermsystemicandmucosalsarscov2igaresponseanditsassociationwithpersistentsmellandtastedisorders AT hawatimera longtermsystemicandmucosalsarscov2igaresponseanditsassociationwithpersistentsmellandtastedisorders AT fannyjarjaval longtermsystemicandmucosalsarscov2igaresponseanditsassociationwithpersistentsmellandtastedisorders AT carinehejl longtermsystemicandmucosalsarscov2igaresponseanditsassociationwithpersistentsmellandtastedisorders AT carinehejl longtermsystemicandmucosalsarscov2igaresponseanditsassociationwithpersistentsmellandtastedisorders AT emmanuellebillondenis longtermsystemicandmucosalsarscov2igaresponseanditsassociationwithpersistentsmellandtastedisorders AT percyimmunocovidgroup longtermsystemicandmucosalsarscov2igaresponseanditsassociationwithpersistentsmellandtastedisorders AT damienricard longtermsystemicandmucosalsarscov2igaresponseanditsassociationwithpersistentsmellandtastedisorders AT damienricard longtermsystemicandmucosalsarscov2igaresponseanditsassociationwithpersistentsmellandtastedisorders AT damienricard longtermsystemicandmucosalsarscov2igaresponseanditsassociationwithpersistentsmellandtastedisorders AT jeannicolastournier longtermsystemicandmucosalsarscov2igaresponseanditsassociationwithpersistentsmellandtastedisorders AT jeannicolastournier longtermsystemicandmucosalsarscov2igaresponseanditsassociationwithpersistentsmellandtastedisorders AT aurelietrignol longtermsystemicandmucosalsarscov2igaresponseanditsassociationwithpersistentsmellandtastedisorders AT aurelietrignol longtermsystemicandmucosalsarscov2igaresponseanditsassociationwithpersistentsmellandtastedisorders AT mariemura longtermsystemicandmucosalsarscov2igaresponseanditsassociationwithpersistentsmellandtastedisorders AT mariemura longtermsystemicandmucosalsarscov2igaresponseanditsassociationwithpersistentsmellandtastedisorders |